Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...

The Case Western Reserve University Science and Human Rights Coalition will host Andrea Waksmunski, a PhD candidate in the Department of Genetics and Genome Sciences, for a talk titled “Ethics of ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

Boston – The Influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally. In the U.S. alone, it is estimated that, despite seasonally ...

A group of Chinese scientists have become the first to use the game-changing gene-editing technology CRISPR-Cas9 on humans. Nature reported today that a team from Sichuan University inserted ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, ...